New Results Highlight the Impact of kidneyintelX.dkd
Recent findings and three presentations at ASN Kidney Week underscore kidneyintelX.dkd as a vital standard for precision medicine in chronic kidney disease (CKD). Renalytix plc, a leader in precision-medicine diagnostics focused on kidney health, has published pivotal data in Diabetes Care, a top-ranking journal in diabetes research.
Overview of the Published Study
The study titled "Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association with Kidney Outcomes in the CANVAS and CREDENCE Trials" showcases insights from leading nephrology and metabolism experts. It evaluated 2,954 patients from the significant CANVAS and CREDENCE trials, representing a comprehensive population for kidneyintelX.dkd's intended use.
Key Findings from the Study
Key findings emphasize that kidneyintelX.dkd significantly enhances CKD risk prediction. For patients evaluated, it provided a more accurate assessment of CKD progression risk and potential for kidney failure. Additionally, in patients classified as moderate or high risk, those treated with SGLT2 inhibitors showed marked reductions in kidneyintelX.dkd risk levels within a year. Notably, high-risk patients exhibited double the likelihood of risk improvement compared to untreated individuals.
Expert Opinions on Clinical Applications
Associate Professor Brendon Neuen from The George Institute for Global Health shared his insights, stating, "With multiple recent breakthroughs in therapies to reduce kidney function decline, the time for risk-based implementation in CKD has arrived. Incorporating novel biomarkers, as exemplified by kidneyintelX.dkd, shows great promise for guiding risk-based care. These new data serve as a compelling demonstration of how we can enhance personalized care and mitigate adverse outcomes."
Presentations at ASN Kidney Week 2025
Renalytix presented three new abstracts at ASN Kidney Week, focusing on the real-world application, clinical utility, and performance advantages of kidneyintelX.dkd:
1. Implementation in a Large Integrated Health System
This study highlighted a comprehensive approach to deploying kidneyintelX.dkd, establishing a sustainable adoption framework that enhances care management across a major health network.
2. Decision-Impact Study in Community Practice
Results indicated that 87% of patients gained a better understanding of their kidney risks while 98% stated that the test increased their awareness of kidney health importance. Moreover, 86% of physicians noted that kidneyintelX.dkd influenced their care decisions significantly.
3. Superior Prediction vs. KFRE
The findings demonstrated that kidneyintelX.dkd outperformed the Kidney Failure Risk Equation (KFRE) in forecasting kidney function decline in diabetic kidney disease, showing superior reliability, especially in early-stage cases.
Setting a New Standard in CKD Precision Medicine
Throughout various clinical trials and head-to-head comparisons, kidneyintelX.dkd continuously demonstrated incremental value, marking its essential role in precision medicine. These results underline its potential as a transformative tool in integrated care management, driving significant advancements in patient outcomes.
Global Impact of Chronic Kidney Disease
Chronic Kidney Disease affects approximately 850 million individuals globally, showcasing its prominence as a public health concern. In many cases, people remain unaware of their condition, highlighting the critical need for effective diagnostic tools like kidneyintelX.dkd.
About Renalytix
Renalytix plc specializes in artificial intelligence-driven diagnostics aimed at improving clinical management of kidney disease. With FDA approval and widespread Medicare reimbursement, kidneyintelX.dkd is commercially available, further enhancing patient care. For more information, visit renalytix.com.
Frequently Asked Questions
1. What is kidneyintelX.dkd?
kidneyintelX.dkd is the only FDA-approved prognostic test for assessing early-stage risk in chronic kidney disease.
2. How does kidneyintelX.dkd improve CKD management?
The test enhances risk prediction and provides tailored treatment guidance for patients classified as moderate or high risk.
3. What were the key findings from the recent study?
The study showed improved risk prediction and treatment outcomes for patients treated with SGLT2 inhibitors compared to untreated individuals.
4. Who conducted the research on kidneyintelX.dkd?
The research was conducted by leading nephrology and metabolism experts from various regions, including the US and Europe.
5. What is Renalytix's mission?
Renalytix aims to optimize clinical management of kidney disease to improve outcomes through advanced diagnostic tools.
